NTRX-07 is a novel therapeutic candidate being developed by NeuroTherapia Inc. (Gates Mills, OH) for the treatment of Alzheimer's disease (AD). This Phase 2 clinical trial (NCT07058688) is evaluating approximately 48 participants with a novel cholinergic anti-inflammatory mechanism that targets neuroinflammation through modulation of the cholinergic anti-inflammatory pathway[1].
NeuroTherapia is targeting the cholinergic anti-inflammatory pathway — a neuroimmune regulatory mechanism distinct from cholinergic neurotransmission in memory and cognition. This approach addresses neuroinflammation, which has emerged as a key pathological feature in Alzheimer's disease beyond amyloid and tau pathology[2].
| Attribute | Details |
|---|---|
| NCT Number | NCT07058688 |
| Sponsor | NeuroTherapia Inc. |
| Drug | NTRX-07 |
| Phase | Phase 2 |
| Indication | Alzheimer's Disease |
| Status | Active, not recruiting (as of 2026-03) |
| Participants | ~48 |
| Study Start | 2024 |
| Location | United States |
The cholinergic anti-inflammatory pathway (CAP) is a neuroimmune regulatory mechanism mediated by the vagus nerve[3]:
Neuroinflammation has emerged as a critical component of AD pathophysiology:
The cholinergic anti-inflammatory approach aims to:
Current approved AD therapies (donepezil, rivastigmine, galantamine) are acetylcholinesterase inhibitors that enhance cholinergic neurotransmission. NTRX-07 takes a different approach:
| Feature | Acetylcholinesterase Inhibitors | NTRX-07 |
|---|---|---|
| Primary target | Cholinergic neurotransmission | Neuroimmune modulation |
| Mechanism | Increase synaptic ACh | Activate α7nAChR on immune cells |
| Indication | Symptomatic treatment | Disease modification |
| Effect location | CNS neurons | Peripheral immune system |
The ~48 participant size suggests an early Phase 2 trial focused on:
This is characteristic of a first-in-human or early Phase 2 study for a novel mechanism.
NeuroTherapia Inc. is a biotechnology company focused on developing novel immunomodulatory therapies for neurodegenerative diseases.
The amyloid cascade hypothesis has been Modified to include neuroinflammation:
This has led to interest in anti-inflammatory therapies, though previous attempts (NSAIDs) have shown limited efficacy in clinical trials.
NTRX-07 represents a novel anti-inflammatory approach:
Activation of the cholinergic anti-inflammatory pathway is generally well-tolerated:
Cai Z, et al. Neuroinflammation in Alzheimer's disease and therapeutic strategies. Cellular & Molecular Neurobiology. 2023. ↩︎
Pavlov VA, et al. Cholinergic anti-inflammatory pathway: vagal modulation of inflammatory diseases. Neuroscience & Biobehavioral Reviews. 2020. ↩︎
Zhang Y, et al. CST7 (Cystatin F) is a biomarker and regulator of microglial activity. Journal of Neuroinflammation. 2022. ↩︎
Ulmann L, et al. TREM2 ligands as immunotherapeutic targets in Alzheimer disease. Nature Reviews Neurology. 2023. ↩︎